Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Portage Biotech Inc Ord (NQ: PRTG )

4.090 +0.140 (+3.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Portage Biotech Inc Ord

“Stocks Under $1 Gaining Momentum: WBUY, KAVL, OMEX, PRTG, RJDG – Driving Innovation, Market Trends, and Growth Potential”
Via AB Newswire
Portage Biotech CEO Interview Explains Why His Company Can Be Poised To Break Higher In 2H 2021 (NASDAQ: PRTG)
Via AB Newswire
Portage Biotech Added to Russell 2000(R) Index
Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology... 
Via Newsfile
Portage Biotech Inc. Announces Pricing of Public Offering of 1,000,000 Ordinary Shares
Westport, Connecticut--(Newsfile Corp. - June 24, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Portage Biotech Inc. Announces Proposed Offering of Ordinary Shares
Westport, Connecticut--(Newsfile Corp. - June 23, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology... 
Via Newsfile
Topics Regulatory Compliance
Exposures Legal Regulatory
Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting
- Data from the IT-01 trial demonstrate the safety of INT230-6... 
Via Newsfile
Portage Biotech Announces Voluntary Delisting from the Canadian Securities Exchange
Westport, Connecticut--(Newsfile Corp. - April 16, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a... 
Via Newsfile
Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors
- Novel platform allows co-targeting of iNKT cells and tumor antigens... 
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.